secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001104659-23-067541
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics holds 2023 annual meeting; elects directors, approves say-on-pay, ratifies auditor
--------------------------------------------------------------------------------

- Elected Martin Vogelbaum and Lisa von Moltke as directors for terms expiring at 2026 annual meeting.
- Non-binding say-on-pay approved: 26,928,795 for, 7,711,887 against, 71,219 abstentions.
- Ratified Ernst & Young as independent auditor for FY2023: 43,767,233 for, 179,748 against, 66,965 abstain.
- Broker non-votes on director elections and say-on-pay totaled 9,302,045.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923067541/0001104659-23-067541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923067541/tm2317673d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-067541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer